MCRB Seres Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MCRB

Price (delayed)

$1.145

Market cap

$172.91M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.89

Enterprise value

$250.69M

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to ...

Highlights
The EPS has soared by 61% YoY and by 21% QoQ
Seres Therapeutics's net income has soared by 55% YoY and by 19% from the previous quarter
The equity has shrunk by 197% QoQ
The quick ratio fell by 40% QoQ and by 33% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.serestherapeutics.com
Peers: AGIO XNCR BIIB RGEN

Key stats

What are the main financial stats of MCRB
Market
Shares outstanding
151.01M
Market cap
$172.91M
Enterprise value
$250.69M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.98
Earnings
Revenue
$126.33M
EBIT
-$100.55M
EBITDA
-$85.43M
Free cash flow
-$125.33M
Per share
EPS
-$0.89
Free cash flow per share
-$0.98
Book value per share
-$0.35
Revenue per share
$0.99
TBVPS
$2.8
Balance sheet
Total assets
$358.6M
Total liabilities
$403.46M
Debt
$213.94M
Equity
-$44.86M
Working capital
$76.75M
Liquidity
Debt to equity
-4.77
Current ratio
1.78
Quick ratio
1.47
Net debt/EBITDA
-0.91
Margins
EBITDA margin
-67.6%
Gross margin
100%
Net margin
-90%
Operating margin
-85.5%
Efficiency
Return on assets
-32.4%
Return on equity
N/A
Return on invested capital
-32.7%
Return on capital employed
-38.7%
Return on sales
-79.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MCRB stock price

How has the Seres Therapeutics stock price performed over time
Intraday
3.15%
1 week
39.63%
1 month
57.8%
1 year
-78.07%
YTD
-18.21%
QTD
47.91%

Financial performance

How have Seres Therapeutics's revenue and profit performed over time
Revenue
$126.33M
Gross profit
$126.33M
Operating income
-$107.98M
Net income
-$113.72M
Gross margin
100%
Net margin
-90%
The operating margin has soared by 98% YoY and by 20% from the previous quarter
MCRB's net margin has surged by 97% year-on-year and by 19% since the previous quarter
MCRB's operating income has surged by 56% year-on-year and by 21% since the previous quarter
Seres Therapeutics's net income has soared by 55% YoY and by 19% from the previous quarter

Growth

What is Seres Therapeutics's growth rate over time

Valuation

What is Seres Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.98
The EPS has soared by 61% YoY and by 21% QoQ
The equity has shrunk by 197% QoQ
The stock's price to sales (P/S) is 97% less than its last 4 quarters average of 37.0 and 97% less than its 5-year quarterly average of 33.6

Efficiency

How efficient is Seres Therapeutics business performance
The ROS has soared by 98% YoY and by 22% QoQ
The return on invested capital has surged by 79% year-on-year and by 28% since the previous quarter
The company's return on assets has surged by 59% YoY and by 20% QoQ

Dividends

What is MCRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MCRB.

Financial health

How did Seres Therapeutics financials performed over time
The total assets is 11% lower than the total liabilities
The quick ratio fell by 40% QoQ and by 33% YoY
MCRB's current ratio is down by 34% QoQ and by 22% YoY
The equity has shrunk by 197% QoQ
Seres Therapeutics's debt to equity has shrunk by 132% YoY but it has surged by 66% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.